VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
CCRN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
CCRNCross Country Healthcare, Inc.
$13.21$427M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksCCRNFinancials

Cross Country Healthcare, Inc. (CCRN) Financials

27Y historyFree accessUpdated daily

Revenue contraction remains persistent, with a 17.8% year-over-year decline in 2026Q1 contributing to a compressed gross margin of 18.2% and negative operating income.

CCRN Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99
Sales/Revenue1B1.05B1.34B2.02B2.8B1.68B836.42M822.22M816.48M865.05M833.54M767.42M617.83M438.31M442.63M503.99M468.56M578.24M734.25M718.27M655.15M645.39M654.11M686.93M639.95M500.5M367.69M193.77M
Revenue Growth %-20.37%-21.56%-33.46%-27.95%67.2%100.46%1.73%0.7%-5.61%3.78%8.62%24.21%40.96%-0.98%-12.17%7.56%-18.97%-21.25%2.22%9.63%1.51%-1.33%-4.78%7.34%27.86%36.12%89.75%-
Cost of Goods Sold803.11M857.52M1.07B1.57B2.18B1.3B633.68M618.22M606.92M636.46M611.8M570.06M460.02M324.85M331.05M366.04M336.25M420.86M541.66M543.61M502.47M503.1M509.57M519.96M478.55M374.65M273.09M148.22M
COGS % of Revenue-81.34%79.59%77.7%77.72%77.63%75.76%75.19%74.33%73.58%73.4%74.28%74.46%74.11%74.79%72.63%71.76%72.78%73.77%75.68%76.69%77.95%77.9%75.69%74.78%74.86%74.27%76.49%
Gross Profit198.84M196.78M274.25M450.41M624.46M375M202.73M204.01M209.56M228.59M221.74M197.37M157.8M113.46M111.58M137.94M132.31M157.38M192.59M174.66M152.68M142.29M144.54M166.97M161.4M125.85M94.6M45.55M
Gross Margin %19.84%18.66%20.41%22.3%22.28%22.37%24.24%24.81%25.67%26.42%26.6%25.72%25.54%25.89%25.21%27.37%28.24%27.22%26.23%24.32%23.31%22.05%22.1%24.31%25.22%25.14%25.73%23.51%
Gross Profit Growth %--28.25%-39.11%-27.87%66.52%84.97%-0.63%-2.65%-8.32%3.09%12.35%25.07%39.08%1.68%-19.11%4.26%-15.93%-18.28%10.26%14.4%7.31%-1.56%-13.43%3.45%28.25%33.04%107.67%-
Operating Expenses219.72M200.24M291.12M337.7M354.58M235.69M211.89M219.72M192.01M197.61M189M169.34M148.46M112.3M116.58M127.4M121.17M137.95M392.66M132.65M124.51M112.56M107.98M118.99M102.73M87.4M65.77M176.12M
OpEx % of Revenue-18.99%21.66%16.72%12.65%14.06%25.33%26.72%23.52%22.84%22.67%22.07%24.03%25.62%26.34%25.28%25.86%23.86%53.48%18.47%19%17.44%16.51%17.32%16.05%17.46%17.89%90.89%
Selling, General & Admin147.11M200.68M254.81M314.95M324.21M220.04M176.84M183.97M182.43M189.26M180.41M162.27M142.03M106.12M109.42M116.54M108.98M124.82M137.77M124.25M110.63M105.97M100.49M110.9M95.17M69.67M49.46M21.95M
SG&A % of Revenue-19.03%18.96%15.59%11.56%13.12%21.14%22.37%22.34%21.88%21.64%21.15%22.99%24.21%24.72%23.12%23.26%21.59%18.76%17.3%16.89%16.42%15.36%16.14%14.87%13.92%13.45%11.33%
Research & Development0000000000000000000000000000
R&D % of Revenue----------------------------
Other Operating Expenses3.06M-441K36.31M22.74M30.37M15.65M35.05M35.75M418K155K230K306K30K119K-16K10.86M12.19M12.79M254.9M8.39M13.88M6.58M7.48M8.09M7.56M17.74M16.31M154.18M
Operating Income-20.88M-3.46M-16.86M112.71M269.88M139.3M-9.16M-15.71M-12.88M11.75M6.18M20.57M-10.47M-8.02M-24.52M10.54M376K17.7M-200.08M42.02M28.18M29.73M36.56M47.98M58.67M38.45M28.82M17.65M
Operating Margin %-2.08%-0.33%-1.25%5.58%9.63%8.31%-1.1%-1.91%-1.58%1.36%0.74%2.68%-1.69%-1.83%-5.54%2.09%0.08%3.06%-27.25%5.85%4.3%4.61%5.59%6.98%9.17%7.68%7.84%9.11%
Operating Income Growth %-79.47%-114.96%-58.24%93.73%1620.79%41.7%-21.98%-209.64%89.97%-69.93%296.46%-30.49%67.28%-332.6%2703.46%-97.88%108.85%-576.15%49.13%-5.23%-18.68%-23.8%-18.22%52.6%33.4%63.26%-
EBITDA-5.19M13.33M635K131.06M282.46M148.76M411K-4.54M-1.1M21.92M15.37M28.63M-3.03M-1.84M-17.35M20.82M12.27M30.49M-189.27M50.53M35.34M37.28M44.11M56.11M65.34M56.19M43.85M22.94M
EBITDA Margin %-0.52%1.26%0.05%6.49%10.08%8.87%0.05%-0.55%-0.13%2.53%1.84%3.73%-0.49%-0.42%-3.92%4.13%2.62%5.27%-25.78%7.03%5.39%5.78%6.74%8.17%10.21%11.23%11.92%11.84%
EBITDA Growth %-65.75%1999.53%-99.52%-53.6%89.88%36093.67%109.06%-312.36%-105.02%42.67%-46.33%1045.85%-64.33%89.38%-183.31%69.72%-59.76%116.11%-474.57%42.97%-5.2%-15.48%-21.38%-14.14%16.3%28.14%91.15%-
D&A (Non-Cash Add-back)15.69M16.79M17.5M18.35M12.58M9.45M9.57M11.18M11.78M10.17M9.18M8.07M7.44M6.18M7.17M10.28M11.89M12.79M10.8M8.51M7.17M7.55M7.55M8.12M6.67M17.74M15.02M5.29M
EBIT-82.89M-3.46M-725K110.99M267.49M145.1M16.32M8.87M-12.54M8.52M32.14M27.02M-27.16M-9.19M-24.55M6.47M-3.71M17.83M-199.94M42.02M28.18M28.37M36.56M48.32M57.57M39.69M28.82M-130.57M
Net Interest Income1.18M913K-138K-8.09M-14.38M-6.87M-2.89M-5.31M-5.65M-4.21M-6.11M-6.81M-4.16M-849K-2.34M-2.86M-4.24M-6.17M-4.22M-2.59M-1.46M-3.46M-4.02M-4.32M-3.75M-14.42M-15.44M0
Interest Income3.42M3.13M2.05M010K00000000000000000000000
Interest Expense2.24M2.22M2.19M8.09M14.39M6.87M2.89M5.31M5.65M4.21M6.11M6.81M4.16M849K2.34M2.86M4.07M6.17M4.22M2.59M1.46M3.46M4.02M4.32M3.75M14.42M15.44M0
Other Income/Expense-65.46M-80.05M467K-9.82M-16.78M-6.1M-3.17M-8.5M-5.32M-7.45M-1.64M-16.41M-20.85M-2.02M-2.38M-2.31M38.29K-8.12M-248.19M-2.68M-1.46M-4.82M-4.02M-5.28M-3.73M-22.42M-15.44M-5.24M
Pretax Income-86.34M-83.51M-16.4M102.89M253.1M133.21M-12.33M-24.21M-18.2M4.3M4.54M4.16M-31.32M-10.04M-26.89M8.23M-3.77M11.65M-204.17M39.34M26.71M24.92M32.54M42.7M54.92M24.03M13.39M12.41M
Pretax Margin %-8.62%-7.92%-1.22%5.09%9.03%7.94%-1.47%-2.94%-2.23%0.5%0.55%0.54%-5.07%-2.29%-6.08%1.63%-0.8%2.02%-27.81%5.48%4.08%3.86%4.97%6.22%8.58%4.8%3.64%6.41%
Income Tax12.28M11.34M-1.84M30.26M67.11M1.21M-188K31.73M-2.48M-34.5M-4.19M-794K216K26.83M-6.15M4.13M-997K4.96M-61.22M14.76M10.15M9.58M11.94M16.53M21.25M10.36M6.73M672K
Effective Tax Rate %-14.23%-13.58%11.23%29.41%26.52%0.91%1.52%-131.06%13.62%-802.16%-92.1%-19.09%-0.69%-267.23%22.87%50.21%26.43%42.56%29.99%37.52%37.98%38.43%36.68%38.7%38.7%43.14%50.28%5.41%
Net Income-98.63M-94.85M-14.56M72.63M185.98M132M-12.96M-57.71M-16.95M37.51M7.97M4.42M-31.78M-34.59M-42.22M4.1M-2.77M6.69M-142.94M24.58M16.64M14.75M20.66M25.82M29.78M8.67M4.6M11.54M
Net Margin %-9.84%-9%-1.08%3.6%6.63%7.87%-1.55%-7.02%-2.08%4.34%0.96%0.58%-5.14%-7.89%-9.54%0.81%-0.59%1.16%-19.47%3.42%2.54%2.29%3.16%3.76%4.65%1.73%1.25%5.96%
Net Income Growth %-456.03%-551.64%-120.04%-60.95%40.89%1118.38%77.54%-240.47%-145.19%370.85%80.33%113.9%8.1%18.09%-1130.28%247.68%-141.45%104.68%-681.56%47.75%12.77%-28.59%-19.99%-13.3%243.43%88.6%-60.17%-
Net Income (Continuing)-98.63M-94.85M-14.56M72.63M185.98M132M-12.14M-55.94M-15.72M38.8M8.73M4.95M-31.53M-54.25M-20.75M4.1M-5.26M6.69M-142.94M24.58M16.57M15.34M20.6M26.38M33M9.62M6.66M11.74M
Discontinued Operations00000000000002.28M00000070.04K0000000
Minority Interest000000534K868K670K630K559K496K454K000000000000000
EPS (Diluted)-3.13-2.93-0.442.055.023.53-0.34-1.56-0.481.010.150.14-1.02-1.12-1.370.13-0.090.22-4.610.760.510.450.630.790.880.340.200.50
EPS Growth %-472.55%-565.91%-121.46%-59.16%42.21%1138.24%78.21%-225%-147.52%573.33%7.14%113.73%8.93%18.25%-1153.85%245.58%-140.59%104.77%-706.58%49.02%13.33%-28.57%-20.25%-10.23%158.82%70%-60%-
EPS (Basic)--2.93-0.442.075.093.60-0.34-1.56-0.481.070.250.14-1.02-1.12-1.370.13-0.090.22-4.640.770.520.460.650.800.920.350.200.50
Diluted Shares Outstanding31.47M32.41M33.38M35.48M37.54M37.39M36.09M35.81M35.66M36.17M36.25M32.16M31.19M31.01M30.84M31.19M31.06M31M31.01M32.48M32.74M32.77M32.58M32.53M33.65M25.22M23.21M23.21M
Basic Shares Outstanding31.47M32.41M33.38M35.16M37.01M36.69M36.09M35.81M35.31M35.02M32.13M31.51M31.16M31M30.84M31.15M31.06M30.82M30.83M31.97M32.08M32.23M31.99M32.09M32.43M24.88M23.21M23.21M
Dividend Payout Ratio----------------------------

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Structural Revenue Normalization

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Persistent Revenue Contraction Trends

As indicated by the most recent quarterly data, CCRN's revenue has experienced a sustained decline, with a 17.8% year-over-year contraction in 2026Q1, reflecting the ongoing normalization of demand for contingent healthcare labor following the elevated activity levels observed during the pandemic-era market peak.

The consistent double-digit revenue declines suggest that the company is struggling to find a stable floor in a post-pandemic environment. This trend appears to be driven by a combination of reduced hospital utilization of travel nurses and a broader cooling of the healthcare staffing market.

Structural Margin Compression Remains Evident

Based on reported financial statements, CCRN's gross margin has compressed to 18.2% in 2026Q1, down from historical levels, highlighting the difficulty in maintaining pricing power as the bill-pay spread narrows amidst a more competitive and cost-conscious hospital procurement environment for temporary clinical staffing.

The inability to sustain gross margins above the 20% threshold suggests that the company lacks the pricing leverage to offset rising clinician pay requirements. Investors should monitor whether this margin erosion is a permanent feature of the current business mix or a temporary cyclical trough.

Operating Leverage Remains Under Pressure

According to recent SEC filings, CCRN's operating income has turned negative, reaching -0.8% in 2026Q1, which demonstrates that the company has not yet successfully aligned its fixed SG&A cost structure with the significantly lower revenue base currently being generated by its core staffing segments.

The failure to achieve positive operating income indicates that the company's overhead remains too high relative to its current volume. This lack of operating leverage suggests that management may need to implement more aggressive cost-rationalization measures to return to profitability.

Earnings Quality Obscured by Losses

As reported in financial statements, CCRN's net income has remained consistently negative, with a net margin of -1.8% in 2026Q1, suggesting that the company's bottom-line performance is currently burdened by both operational inefficiencies and the lack of non-operating income to offset core business losses.

The persistent net losses raise concerns regarding the quality of earnings, as the company is currently unable to generate positive returns for shareholders. The absence of significant stock-based compensation in recent quarters may indicate a lack of incentive alignment or a pause in equity-based compensation programs during this downturn.

Downside Risks to Recovery Narrative

Based on the provided financial data, the primary risk to the investment thesis is that the current revenue contraction is not merely cyclical but reflects a permanent shift in hospital staffing preferences that could keep CCRN's operating margins in negative territory for an extended period.

Short-sellers would likely focus on the company's inability to return to profitability despite a clean balance sheet. If the company cannot demonstrate a clear path to margin expansion, the current cash position may be depleted by ongoing operating losses rather than being used for strategic growth.

CCRN — Frequently Asked Questions

Quick answers to the most common questions about buying CCRN stock.

What was Cross Country Healthcare, Inc.'s (CCRN) revenue in 2025?

For fiscal year 2025, Cross Country Healthcare, Inc. (CCRN) reported total revenue of $1.05B. This represents a 444.1% increase compared to $193.8M in 1999.

Is Cross Country Healthcare, Inc. (CCRN) profitable?

Cross Country Healthcare, Inc. (CCRN) reported a net loss of $94.9M for the fiscal year ending 2025.

What is Cross Country Healthcare, Inc.'s operating profit margin?

Cross Country Healthcare, Inc. (CCRN) reported an operating income of $-3.5M, resulting in an operating profit margin of -0.3%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Cross Country Healthcare, Inc.'s gross profit and gross margin?

Cross Country Healthcare, Inc. (CCRN) generated $196.8M in gross profit for the year, representing a gross profit margin of 18.7%. This demonstrates the company's core pricing power and production efficiency.